Proaktivní režim v léčbě atopické dermatitidy

Číslo: 3 / 2010 (Obsah)
Rubrika: Farmakoterapeutické postupy
Obor: Dermatologie
Autoři: MUDr. Radek Litvik
Autoři - působiště: Kožní oddělení, Fakultní nemocnice Ostrava
Citace: 1 Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969–87. 2 Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003;326:1367–72. 3 Bieber T, Braun-Falco O. IgE-bearing Langerhans cells are not specific to atopic eczema but are found in inflammatory skin diseases. J Am Acad Dermatol 1991;24:658–9. 4 Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992;175:1285–90. 5 Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192–9. 6 Darsow U, Lubbe J, Taieb A, et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286–95. 7 Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528–37. 8 Kerschenlohr K, Darsow U, Burgdorf WHC, et al. Lessons of atopy patch testing in atopic dermatitis. Curr Allergy Asthma Rep 2004;4:285–9. 9 Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002;119:166–73. 10 Mihm MC, Soter NA, Dvorak HF, et al. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305–12. 11 Ogawa H, Yoshiike T. Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992;9:383–5. 12 Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6. 13 Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008;158:801–7. 14 Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006;118:214–9. 15 Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985;65:102–5. 16 Wollenberg A, Reitamo S, Girolomoni G, et al. A novel approach to disease control with 0,1% tacrolimus ointment in adults with atopic dermatitis: results of a randomized, multicentre, comparative study. Allergy 2008;63:742–50. 17 Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy 2009;64:276–8. 18 Cork MJ et al. Dermatology Update. Montreal, Canada; 6–7 Nov 2003. 19 Taylor B, Wadsworth J, Wadsworth M, et al. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984;2:1255–7. 20 Diepgen TL. Is the prevalence of atopic dermatitis increasing? In: Williams HC, eds. Atopic Dermatitis. Cambridge: Cambridge University Press, 2000. 21 Stensen L, Thomsen SF, Backer V. Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc 2008;29:392–6. 22 Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44(Suppl):S1–S12. 23 Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483–94. 24 Astellas Pharma EU. Data on file 2007: FG-506-06-4

Souhrn

Atopická dermatitida (AD) je chronické, recidivující svědivé kožní onemocnění vyznačující se suchou kůží a zánětlivou reakcí se širokým spektrem klinických projevů. Jedná se o nepřiměřenou reakci imunitního systému organismu na jinak zcela neškodné látky či podněty ze zevního prostředí, včetně potravy, při současně porušené bariérové funkci kůže. Výskyt AD se v rozvinutých zemích během posledních 30 let dramaticky zvýšil, a to dvoj- až trojnásobně (prevalence u dětí 15–30 %, prevalence v dospělé populaci 2–10 %) (obrázek 1).

Literatura

1 Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969–87. 2 Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003;326:1367–72. 3 Bieber T, Braun-Falco O. IgE-bearing Langerhans cells are not specific to atopic eczema but are found in inflammatory skin diseases. J Am Acad Dermatol 1991;24:658–9. 4 Bieber T, de la Salle H, Wollenberg A, et al. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1992;175:1285–90. 5 Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005;22:192–9. 6 Darsow U, Lubbe J, Taieb A, et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286–95. 7 Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528–37. 8 Kerschenlohr K, Darsow U, Burgdorf WHC, et al. Lessons of atopy patch testing in atopic dermatitis. Curr Allergy Asthma Rep 2004;4:285–9. 9 Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002;119:166–73. 10 Mihm MC, Soter NA, Dvorak HF, et al. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976;67:305–12. 11 Ogawa H, Yoshiike T. Atopic dermatitis: studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992;9:383–5. 12 Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6. 13 Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008;158:801–7. 14 Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006;118:214–9. 15 Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985;65:102–5. 16 Wollenberg A, Reitamo S, Girolomoni G, et al. A novel approach to disease control with 0,1% tacrolimus ointment in adults with atopic dermatitis: results of a randomized, multicentre, comparative study. Allergy 2008;63:742–50. 17 Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy 2009;64:276–8. 18 Cork MJ et al. Dermatology Update. Montreal, Canada; 6–7 Nov 2003. 19 Taylor B, Wadsworth J, Wadsworth M, et al. Changes in the reported prevalence of childhood eczema since the 1939-45 war. Lancet 1984;2:1255–7. 20 Diepgen TL. Is the prevalence of atopic dermatitis increasing? In: Williams HC, eds. Atopic Dermatitis. Cambridge: Cambridge University Press, 2000. 21 Stensen L, Thomsen SF, Backer V. Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc 2008;29:392–6. 22 Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44(Suppl):S1–S12. 23 Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483–94. 24 Astellas Pharma EU. Data on file 2007: FG-506-06-4

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky